Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isoquercetin in Stable Sickle Cell Disease
NCT04514510Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Nov 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of isoquercetin in sickle cell disease (SCD), sponsored by National Heart, Lung, and Blood Institute. Started Nov 2020; status: completed.
02
Drugs
isoquercetin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04514510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04514510.